

## CURRICULUM VITAE

---

**DATE PREPARED:** April 2018

**Name:** Steven J. Skates

**Education:**

- 1979 B.Sc.(1<sup>st</sup> class honors), University of Western Australia (Mathematics)
- 1987 Ph.D., University of Chicago, Chicago, IL (Statistics)

**Academic Appointments:**

- 1986 – 1988 Research Fellow in Medicine, Harvard Medical School
- 1988 – 1991 Instructor in Medicine (Biostatistics), Harvard Medical School
- 1991 – 2008 Assistant Professor of Medicine (Biostatistics), Harvard Medical School
- 2008 – Associate Professor of Medicine (Biostatistics), Harvard Medical School

**Major Committee Assignments:**

- 1994 Task Force on Clinical Research, Infrastructure Subcommittee, Massachusetts General Hospital
- 1998 – 2001 Subcommittee for Review of Research Proposals (SRRP), Massachusetts General Hospital
- 2001 – present Trial Management Committee, United Kingdom Collaborative Trial of Ovarian Cancer Screening
- 2002 NCI Special Emphasis Panel, Cancer Prognosis & Prediction: Phased Application Awards and SBIR/STTR Initiative
- 2007 AACR-FDA-NCI Cancer Biomarkers Collaborative Committee: To develop recommendations to the FDA on cancer biomarkers in clinical trials.
- 2008 American Cancer Society Panel on Ovarian Symptoms Management. To develop consensus recommendations for standards of care for diagnostic work-up of women with pelvic symptoms.
- 2009 Scientific and Medical Advisory Committee, Ovarian Cancer National Alliance (OCNA). To advise OCNA on all aspects of early detection of ovarian cancer research.
- 2009 – 2013 Member, NIAID Clinical Proteomics Center Scientific Working Group
- 2009 – 2010 Member, Protect Your Lungs Scientific Advisory Board
- 2010 Member, Scientific Advisory Board for NCI Alliance of Glycobiologists for Detection of Cancer and Cancer Risk
- 2010 – 2013 Member, Ayers Institute for Pre-cancer Detection, Vanderbilt University, Scientific Advisory Board
- 2010 – 2013 Member, NCI Biospecimen Research Network Scientific Steering Committee
- 2011 – present Member, LUNGeVity Foundation, Scientific Advisory Board
- 2014 Ad-hoc FDA Panel Member, Molecular and Clinical Genetics Panel, FDA's Office of Device Evaluation, Center for Devices and Radiological Health (CDRH), Panel Hearing for two Pre-Marketing Applications (PMA) for Early Detection of Colorectal Cancer, FDA, Silver Spring MD, March 2014

- 2015 – present FDA Panel Member – 4 year term, Molecular and Clinical Genetics Panel
- 2015 – present Consultant to other panels of the Medical Devices Advisory Committee, and to the Center for Devices and Radiological Health (4 year term)
- 2016 Ad hoc member, NCI Cancer Biomarkers Study Section (CBSS)
- 2016 Ad hoc member, NCI Special Emphasis Panel, ZCA1 SRB-5 (J1) NCI Omnibus R03 SEP, September 2016
- 2016 Ad hoc member, FDA Microbiology Devices Panel, meeting for the Application of Procalcitonin to the Evaluation and Management of Suspected Lower Respiratory Tract Infections and Sepsis, Gaithersburg MD, November 2016.
- 2016 Internal Advisory Board (IAB) Member, Center for Innovation in Early Cancer Detection (IECD), MGH Cancer Center
- 2017 Member, NCI Cancer Biomarkers Study Section (CBSS) (4 year term)

**Bibliography:****Original Articles**

1. Keast D, Rowe P, Sanfelieu L, Shannahan J, Bowra B, **Skates SJ**, Stapley EO, Woodruff HB, Use of a computer to group actinomycetes for studies on the ecology of soil microorganisms. *Appl Environ Microbiol.* 1984; 48(4):791-6.
2. Reid WH; **Skates SJ**. On The Asymptotic Approximation of Integrals. *SIAM J Appl Math.* 1986 46(3), 351-358.
3. Willett CG, Tepper JE, **Skates SJ**, Wood WC, Orlow EC, Duttonhaver JR. Adjuvant postoperative radiation therapy for colonic carcinoma. *Ann Surg.* 1987; 206(6):694-8.
4. Willett CG, Linggood RM, Leong JC, Miketic LM, Stracher MA, **Skates SJ**, Kushner DC. Stage IA to IIB mediastinal Hodgkin's disease: three-dimensional volumetric assessment of response to treatment. *J Clin Oncol.* 1988 May;6(5):819-24. PMID:3367187
5. Willett CG, Stracher MA, Linggood RM, Miketic LM, Leong JC, **Skates SJ**, Kushner DC, Jacobson JO. Three-dimensional volumetric assessment of response to treatment: stage I and II diffuse large cell lymphoma of the mediastinum. *Radiother Oncol.* 1988 Jul;12(3):193-8. PMID:3175046
6. Okunieff P, Rummeny E, Vaupel P, **Skates SJ**, Willett C, Neuringer LJ, Suit HD. Effects of pentobarbital anesthesia on the energy metabolism of murine tumors studied by in vivo <sup>31</sup>P nuclear magnetic resonance spectroscopy. *Radiat Res.* 1988 Aug;115(2):361-72. PMID:3406373
7. Austin-Seymour M, Munzenrider J, Goitein M, Verhey L, Urie M, Gentry R, Birnbaum S, Ruotolo D, McManus P, **Skates SJ**, et al. Fractionated proton radiation therapy of chordoma and low-grade chondrosarcoma of the base of the skull. *J Neurosurg.* 1989 Jan;70(1):13-7. PMID:2535872
8. Lauk S, Zietman A, **Skates SJ**, Fabian R, Suit HD. Comparative morphometric study of tumor vasculature in human squamous cell carcinomas and their xenotransplants in athymic nude mice. *Cancer Res.* 1989 Aug 15;49(16):4557-61. PMID:2743340
9. Tolentino FI, Cajita VN, Gancayco T, **Skates SJ**. Vitreous hemorrhage after closed vitrectomy for proliferative diabetic retinopathy. *Ophthalmology.* 1989 Oct;96(10):1495-500. PMID:2587044
10. Lauk S, **Skates SJ**, Goodman M, Suit HD. A morphometric study of the vascularity of oral squamous cell carcinomas and its relation to outcome of radiation therapy. *Eur J Cancer Clin Oncol.* 1989; 25(10):1431-40.
11. Thor AD, Schwartz LH, Koerner FC, Edgerton SM, **Skates SJ**, Yin S, McKenzie SJ, Panicali DL, Marks PJ, Fingert HJ. Analysis of c-erbB-2 expression in breast carcinomas with clinical follow-up. *Cancer Res.* 1989; 49(24 Pt 1):7147-52.
12. Eagle KA, Mulley AG, **Skates SJ**, Reder VA, Nicholson BW, Sexton JO, Barnett GO, Thibault GE. Length of stay in the intensive care unit. Effects of practice guidelines and feedback. *JAMA.* 1990 Aug 22-29;264(8):992-7.
13. **Skates SJ**, Singer DE. Quantifying the potential benefit of a CA-125 screening for ovarian cancer. *J Clin Epidemiol* 1991; 44(4):365-380.
14. Rigotti NA, Neer RM, **Skates SJ**, Herzog DB, Nussbaum SR. The clinical course of osteoporosis in anorexia nervosa: a longitudinal study of cortical bone mass. *JAMA* 1991; 265:1133-1138.
15. Niles JL, Pan GL, Collins AB, Shannon T, **Skates SJ**, Fienberg R, Arnaout MA, McCluskey RT. Antigen-specific radioimmunoassays for anti-neutrophil cytoplasmic antibodies in the diagnosis of rapidly progressive glomerulonephritis. *J Am Soc Nephrol* 1991; 2(1):27-36.

16. Eagle KA, Mulley AG, Field TS, **Skates SJ**, Bero G, Clark CE, Sexton JO, Reder VA, Berrigan G, Procaccini J. Variation in intensive care unit practices in two community hospitals. *Med Care*. 1991 Dec;29(12):1237-45. PMID:1745081
17. Urie MM, Fullerton B, Tatsuzaki H, Birnbaum S, Suit HD, Convery K, **Skates SJ**, Goitein M. A dose response analysis of injury to cranial nerves and/or nuclei following proton beam radiation therapy. *Int J Radiat Oncol Biol Phys*. 1992;23(1):27-39. PMID:1572828
18. Maciejewski BA, **Skates SJ**, Zajusz A, Lange D. Importance of tumor size and repopulation for radiocurability of skin cancer. *Neoplasma*. 1993;40(1):51-4. PMID: 8350948
19. **Skates SJ**. On secant approximations to cumulative distribution functions. *Biometrika* 1993;223-235.
20. Atlas SJ, Singer DE, **Skates SJ**. Changing blood use in the AIDS era: The case of elective hip surgery. *Transfusion* 1994; 34:286-391.
21. Pardo FS, Aronen HJ, Kennedy D, **Skates SJ**, Paiva K, Okunieff P, Schmidt EV, Hochberg FH, Harsh GR, Fishman AJ, Linggood RM, Rosen BR. Functional cerebral imaging in the evaluation and radiotherapeutic treatment planning of patients with malignant glioma. *Int J Rad Oncol Biol Phys* 1994.
22. **Skates SJ**, Xu F-J, Yu Y-H, Sjovall K, Einhorn N, Chang Y, Bast RC, Knapp RC. Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers. *Cancer* 1995; 76:2004-2010.
23. Hylek IM, **Skates SJ**, Sheehan MA, Singer DE. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. *NEJM* 1996; 335(8):540-546.
24. Jacobs IJ, **Skates SJ**, Davies AP, Woolas RP, Jeyarajah A, Weidemann P, Sibley K, Oram DH. Risk of diagnosis of ovarian cancer after raised serum CA 125 concentration: a prospective cohort study. *BMJ*. 1996; 313(7069):1355-8.
25. Merkel PA, Polisson RP, Chang Y, **Skates SJ**, Niles JL. Prevalence of antineutrophil cytoplasmic antibodies in a large inception cohort of patients with connective tissue disease. *Ann Intern Med* 1997; 126(11): 866-73.
26. Barry MJ, Cherkin DC, Chang Y, Fowler FJ, **Skates SJ**. A randomized trial of a multimedia shared decision-making program for men facing a treatment decision for benign prostatic hyperplasia. *Disease Management and Clinical Outcomes*, 1997, 1, 1: 5-14.
27. Hylek EM, Heiman H, **Skates SJ**, Sheehan MA, Singer DE. Acetaminophen and other risk factors for excessive warfarin anticoagulation. *JAMA* 1998; 279(9): 657-62.
28. Lein M, Koenig F, Jung K., McGovern, FJ, **Skates SJ**, Schnorr D, Loening S. A. The percentage of free prostate specific is an age-independent tumour marker for prostate cancer: establishment of reference ranges in a large population of healthy men. *Br J Urol* 1998; 82(2): 231-6.
29. Jacobs IJ, **Skates SJ**, MacDonald N, Menon U, Rosenthal AN, Davies AP, Woolas R, Jeyarajah AR, Sibley K, Lowe DG, Oram DH. Screening for ovarian cancer: a pilot randomized controlled trial. *Lancet*. 1999; 353(9160):1207-10.
30. Jeyarajah AR, Ind TE, MacDonald N, **Skates SJ**, Oram DH, Jacobs IJ. Increased mortality in postmenopausal women with serum CA125 elevation. *Gynecol Oncol*. 1999 May;73(2):242-6. PMID:10329041
31. Jeyarajah AR, Ind TEJ, **Skates SJ**, Oram DH, Jacobs IJ. Serum CA125 elevation and risk of clinical detection of cancer in asymptomatic post-menopausal women. *Cancer*. 85:9, 2068-2072.
32. Menon U, Talaat A, Jeyarajah AR, Rosenthal AN, MacDonald ND, **Skates SJ**, Sibley K, Oram DH, Jacobs. (1999). Ultrasound Assessment of Ovarian Cancer Risk in Postmenopausal Women with CA125 Elevation. *Br. J. Cancer*. 80 (10); 1644-47.

33. Menon U, Talaat A, Rosenthal AN, Macdonald ND, Jeyerajah AR, **Skates SJ**, Sibley K, Oram DH, Jacobs IJ. Performance of ultrasound as a second line test to serum CA125 in ovarian cancer screening. *Br J Obstet Gynaecol*. 2000; 107(2):165-9.
34. Penson RT, **Skates SJ**, Fuller AJ, Seiden MV. Clinical course of stage IV epithelial ovarian cancer. *J Clin Oncol*. 1999; 17(10):3361-2.
35. **Skates SJ**. Optimal summary of information in longitudinal CA125 measurements for efficient ovarian cancer screening. *J Clin Ligand Assay*. 2000, 23(2), 150-154.
36. Jacobs IJ; **Skates SJ**; MacDonald N. Ovarian cancer screening was feasible but did not decrease incidence of index cancer or mortality. *West J Med*. 2000 172(2), 97-7
37. Menon U, Talaat A, Rosenthal AN, Macdonald ND, Jeyerajah AR, **Skates SJ**, Sibley K, Oram DH, Jacobs IJ. Performance of ultrasound as a second line test to serum CA125 in ovarian cancer screening. *BJOG*. 2000 Feb;107(2):165-9. PMID: 10688498
38. Hylek EM; Chang YC; **Skates SJ**; Hughes RA; Singer DE. Prospective study of the outcomes of ambulatory patients with excessive warfarin anticoagulation. *Arch Intern Med*. 2000, 160(11), 1612-17.
39. **Skates SJ**, Jacobs IJ, Knapp RC. Tumor markers in screening for ovarian cancer. *Methods Mol Med*. 2001;39:61-73. doi: 10.1385/1-59259-071-3:61. PMID: 21340758
40. Pauler DK; Menon U; McIntosh M; Symecko HL; **Skates SJ**; Jacobs IJ. Factors influencing serum CA125II levels in healthy postmenopausal women. *Cancer Epi Biomarkers & Prevention*. 2001, 10(5), 489-493.
41. Hylek EM; Regan S; Go AS; Hughes RA; Singer DE; **Skates SJ**. Clinical predictors of prolonged delay in return of the international normalized ratio to within the therapeutic range after excessive anticoagulation with warfarin. *Ann Intern Med* 2001, 135(6), 393-400.
42. Zweemer RP, Verheijen RH, Coebergh JW, Jacobs IJ, van Diest PJ, Gille JJ, **Skates SJ**, Menko FH, Ten Kate LP, Kenemans P. Survival analysis in familial ovarian cancer, a case control study. *Eur J Obstet Gynecol Reprod Biol*. 2001; 98(2):219-23.
43. Mok SC; Chao J; **Skates SJ**; Wong KK; Yiu GK; Muto MG; Berkowitz RS; Cramer DW. Prostatein, a potential serum marker for ovarian cancer: Identification through microarray technology. *JNCI* 2001 93 (19), 1458-64.
44. **Skates SJ**; Pauler DK; Jacobs IJ. Screening based on the risk of cancer calculation from Bayesian hierarchical change-point and mixture models of longitudinal markers. *J Am Stat Assoc*. 2001, 96(454), 429-439.
45. Parmigiani G, **Skates SJ**. Estimating the distribution of the age of onset of detectable asymptomatic cancer. *Mathematical and Computer Modeling*. 2001, 33(12-13), 1347-60.
46. Parmigiani G, **Skates SJ**, Zelen M. Modeling and Optimization in Early Detection Programs with a Single Exam. *Biometrics* 2002; 58(1):30-6.
47. Kim JH, **Skates SJ**, Uede T, Wong Kk KK, Schorge JO, Feltmate CM, Berkowitz RS, Cramer DW, Mok SC. Osteopontin as a potential diagnostic biomarker for ovarian cancer. *JAMA* 2002; 287(13):1671-9.
48. Cannistra SA, Bast RC, Berek JS, Bookman MA, Crum CP DePreist PD, Garber JE, Koh WJ, Markman M, McGuire WP, Rose PG, Rowinsky EK, Rustin GJ, **Skates SJ**, Vasey PA, King L. Progress in the management of gynecologic cancer: consensus summary statement. *J Clin Oncol*. 2003; 21 (10 Suppl): 129-32.
49. **Skates SJ**, Menon U, MacDonald N, Rosenthal AN, Oram DH, Knapp RC, Jacobs IJ. Calculation of the Risk of Ovarian Cancer From Serial CA-125 Values for Preclinical Detection in Postmenopausal Women. *J Clin Oncol*. 2003, 21 (10 Suppl): 206-10.
50. Ye B, Cramer DW, **Skates SJ**, Gygi SP, Pratomo V, Fu L, Horick NK, Licklider LJ, Schorge JO, Berkowitz RS, Mok SC. Haptoglobin-alpha subunit as potential serum biomarker in ovarian cancer: identification and characterization using proteomic profiling and mass spectrometry. *Clin Cancer Res*. 2003; 9(8): 2904-11.

51. **Skates SJ**, Troiano R, Knapp RC. Longitudinal CA125 detection of sporadic papillary serous carcinoma of the peritoneum. *Int J Gynecol Cancer*. 2003; 13(5):693-6.
52. Kim JH, Herlyn D, Wong KK, Park DC, Schorge JO, Lu KH, **Skates SJ**, Cramer DW, Berkowitz RS, Mok SC. Identification of epithelial cell adhesion molecule autoantibody in patients with ovarian cancer. *Clin Cancer Res*. 2003; 9(13): 4782-91.
53. Penson RT, Oliva E, **Skates SJ**, Glyptis T, Fuller AF, Goodman A, Seiden MV. Expression of multi-drug resistance-1 protein inversely correlates with paclitaxel response and survival in ovarian cancer patients: a study in serial samples. *Gynecol Oncol*. 2004; 93(1):98-106.
54. Schorge JO, Drake RD, Lee H, **Skates SJ**, Rajanbabu R, Miller DS, Kim JH, Cramer DW, Berkowitz RS, Mok SC. Osteopontin as an adjunct to CA125 in detecting recurrent ovarian cancer. *Clin Cancer Res*. 2004; 10(10):3474-8.
55. **Skates SJ**, Horick N, Yu Y, Xu F-J, Berchuck A, Havrilesky LJ, de Bruijn HWA, van der Zee AGJ, Woolas RP, Jacobs IJ, Zhang Z, Bast RC. Pre-operative sensitivity and specificity for early stage ovarian cancer when combining CA125II, CA15-3, CA72-4, and M-CSF using mixtures of multivariate Normal distributions. *J Clin Oncol* 2004; 22(20):4059-66.
56. Menon U, **Skates SJ**, Lewis S, Rosenthal AN, Rufford B, Carter K, MacDonald N, Dawnay A, Jeyarajah A, Bast RC, Oram D, Jacobs IJ. Prospective study using the Risk of Ovarian Cancer Algorithm to Screen for Ovarian Cancer. *J Clin Oncol*. 2005; 23(31):7919-26.
57. Ye B, **Skates SJ**, Horick NK, Vitonis AF, Edwards DS, Sluss P, Han WK, Berkowitz RS, Cramer DW, Mok S. Proteomic-Based Discovery and Characterization of Glycosylated Eosinophil-Derived-Neurotoxin and C-Terminal Osteopontin Fragments for Ovarian Cancer in Urine. *Clin Cancer Res*. 2006; 12(2):432-41.
58. **Skates SJ**, Horick NK, Moy JM, Minihan AM, Seiden MV, Marks JR, Sluss P, Cramer DW. Pooling of case specimens to create standard serum sets for screening cancer biomarkers. *Cancer Epidemiol Biomarkers Prev*. 2007; 16(2):334-41.
59. Creaney J, Yeoman D, Naumoff LK, Hof M, Segal A, Musk AW, De Klerk N, Horick N, **Skates SJ**, Robinson BW. Soluble mesothelin in effusions: a useful tool for the diagnosis of malignant mesothelioma. *Thorax*. 2007; 62(7):569-76.
60. Lehman CD, Isaacs C, Schnall MD, Pisano ED, Ascher SM, Weatherall PT, Bluemke DA, Bowen DJ, Marcom PK, Armstrong DK, Domchek SM, Tomlinson G, **Skates SJ**, Gatsonis C. Cancer yield of mammography, MR, and US in high-risk women: prospective multi-institution breast cancer screening study. *Radiology*. 2007; 244(2):381-8.
61. Yurkovetsky Z, Ta'asan S, **Skates SJ**, Rand A, Lomakin A, Linkov F, Marrangoni A, Velikokhatnaya L, Winans M, Gorelik E, Maxwell GL, Lu K, Lokshin A. Development of multimarker panel for early detection of endometrial cancer. High diagnostic power of prolactin. *Gynecol Oncol*. 2007; 107(1):58-65.
62. Creaney J, van Bruggen I, Hof M, Segal A, Musk AW, de Klerk N, Horick N, **Skates SJ**, Robinson BW. Combined CA125 and mesothelin levels for the diagnosis of malignant mesothelioma. *Chest*. 2007; 132(4):1239-46.
63. Zhang Z, Yu Y, Xu F, Berchuck A, van Haaften-Day C, Havrilesky LJ, de Bruijn HW, van der Zee AG, Woolas RP, Jacobs IJ, **Skates SJ**, Chan DW, Bast RC. Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer. *Gynecol Oncol*. 2007; 107(3):526-31.
64. Moore RG, Brown AK, Miller MC, **Skates SJ**, Allard WJ, Verch T, Steinhoff M, Messerlian G, Disilvestro P, Granai CO, Bast RC. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. *Gynecol Oncol*. 2007.
65. Greene MH, Piedmonte M, Alberts D, Gail M, Hensley M, Miner Z, Mai PL, Loud J, Rodriguez G, Basil J, Boggess J, Schwartz PE, Kelley JL, Wakeley KE, Minasian L, **Skates SJ**. A prospective study of risk-reducing salpingo-oophorectomy and longitudinal CA-125 screening among women at increased genetic risk of ovarian cancer: design and baseline

- characteristics: a gynecologic oncology group study. *Cancer Epidemiol Biomarkers Prev.* 2008; 17(3):594-604.
66. Hulick P, Zimmer M, Margulis V, **Skates SJ**, Hamel M, Dahl DM, Michaelson DM, Liebermann T, Signoretti S, Carney W, Wood W, Iliopoulos O. Blood Levels of Carbonic Anhydrase 9 Correlate with Clear Cell Renal Cell Carcinoma Activity. *Clinical Proteomics.* 2008.
  67. Creaney J, Yeoman D, Demelker Y, Segal A, Musk AW, **Skates SJ**, Robinson BW. Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma. *J Thorac Oncol.* 2008; 3(8):851-7.
  68. Drapkin R, Clauss A, **Skates SJ**. Urokinase-type plasminogen activator receptor: A beacon of malignancy? *Clin Can Res* 2008; 14(18):5643-5.
  69. Menon U, Gentry-Maharaj A, Ryan A, Sharma A, Burnell M, Hallett R, Lewis S, Lopez A, Godfrey K, Oram D, Herod J, Williamson K, Seif M, Scott I, Mould T, Woolas R, Murdoch J, Dobbs S, Amso N, Leeson S, Cruickshank D, McGuire A, Campbell S, Fallowfield L, **Skates SJ**, Parmar M, Jacobs I. Recruitment to multicentre trials--lessons from UKCTOCS: descriptive study. *BMJ.* 2008; 337:a2079.
  70. Moore RG, McMeekin SD, Brown AK, DiSilvestro PA, Miller CM; Allard JW, Gajewski W, Kurman RJ, Bast RC; **Skates SJ**. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. *Gynecol Oncol.* 2009; 112(1):40-6.
  71. Menon U, Gentry-Maharaj A, Hallett R, Ryan A, Burnell M, Sharma A, Lewis S, Davies S, Philpott S, Lopes A, Godfrey K, Oram D, Herod J, Williamson K, Seif MW, Scott I, Mould T, Woolas R, Murdoch J, Dobbs S, Amso NN, Leeson S, Cruickshank D, McGuire A, Campbell S, Fallowfield L, Singh N, Dawnay A, **Skates SJ**, Parmar M, Jacobs I. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). *Lancet Oncol.* 2009.
  72. Manchanda R, Rosenthal A, Burnell M, Fraser L, Mackay J, **Skates SJ**. Change in stage distribution observed with annual screening for ovarian cancer in BRCA carriers. *J Med Genet.* 2009 Jun;46(6):423-4. doi: 10.1136/jmg.2009.067462. PMID:19487541
  73. Addona TA, Abbatiello SE, Schilling B, **Skates SJ**, Mani DR, Bunk DM, Spiegelman CH, Zimmerman LJ, Ham AJ, Keshishian H, Hall SC, Allen S, Blackman RK, Borchers CH, Buck C, Cardasis HL, Cusack MP, Dodder NG, Gibson BW, Held JM, Hiltke T, Jackson A, Johansen EB, Kinsinger CR, Li J, Mesri M, Neubert TA, Niles RK, Pulsipher TC, Ransohoff D, Rodriguez H, Rudnick PA, Smith D, Tabb DL, Tegeler TJ, Variyath AM, Vega-Montoto LJ, Wahlander A, Waldemarson S, Wang M, Whiteaker JR, Zhao L, Anderson NL, Fisher SJ, Liebler DC, Paulovich AG, Regnier FE, Tempst P, Carr SA. Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma. *Nat Biotechnol.* 2009 Jul;27(7):633-41. Erratum in: *Nat Biotechnol.* 2009; 27(9):864.
  74. Moore RG, McMeekin DS, Brown AK, DiSilvestro P, Miller MC, Allard WJ, Gajewski W, Kurman R, Bast RC, **Skates SJ**. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. *Gynecol Oncol.* 2009; 112(1):40-6.
  75. Regnier FE, **Skates SJ**, Mesri M, Rodriguez H, Tezak Z, Kondratovich MV, Alterman MA, Levin JD, Roscoe D, Reilly E, Callaghan J, Kelm K, Brown D, Philip R, Carr SA, Liebler DC, Fisher SJ, Tempst P, Hiltke T, Kessler LG, Kinsinger CR, Ransohoff DF, Mansfield E, Anderson NL. Protein-based multiplex assays: mock presubmissions to the US Food and Drug Administration. *Clin Chem.* 2010; 56(2):165-71.

76. Yurkovetsky Z, **Skates SJ**, Lomakin A, Nolen B, Pulsipher T, Modugno F, Marks J, Godwin A, Gorelik E, Jacobs I, Menon U, Lu K, Badgwell D, Bast RC, Lokshin AE. Development of a multimarker assay for early detection of ovarian cancer. *J Clin Oncol*. 2010; 28(13):2159-66.
77. Creaney J, Olsen NJ, Brims F, Dick IM, Musk AW, de Klerk NH, **Skates SJ**, Robinson BW. Serum mesothelin for early detection of asbestos-induced cancer malignant mesothelioma. *Cancer Epidemiol Biomarkers Prev*. 2010; 19(9):2238-46.
78. Moore RG, Jabre-Raughley M, Brown AK, Robison KM, Miller MC, Allard WJ, Kurman RJ, Bast RC, **Skates SJ**. Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass. *Am J Obstet Gynecol*. 2010.
79. Jacobs I, Gentry-Maharaj A, Burnell M, Manchanda R, Singh N, Sharma A, Ryan A, Seif MW, Amso NN, Turner G, Brunell C, Fletcher G, Rangar R, Ford K, Godfrey K, Lopes A, Oram D, Herod J, Williamson K, Scott I, Jenkins H, Mould T, Woolas R, Murdoch J, Dobbs S, Leeson S, Cruickshank D, **Skates SJ**, Fallowfield L, Parmar M, Campbell S, Menon U. Sensitivity of transvaginal ultrasound screening for endometrial cancer in postmenopausal women: a case-control study within the UKCTOCS cohort. *Lancet Oncol*. 2011; 12(1):38-48.
80. Burnell M, Gentry-Maharaj A, Ryan A, Apostolidou S, Habib M, Kalsi J, **Skates SJ**, Parmar M, Seif MW, Amso NN, Godfrey K, Oram D, Herod J, Williamson K, Jenkins H, Mould T, Woolas R, Murdoch J, Dobbs S, Leeson S, Cruickshank D, Campbell S, Fallowfield L, Jacobs I, Menon U. Impact on mortality and cancer incidence rates of using random invitation from population registers for recruitment to trials. *Trials*. 2011; 12:61.
81. Cramer DW, Bast RC, Berg CD, Diamandis EP, Godwin AK, Hartge P, Lokshin AE, Lu KH, McIntosh MW, Mor G, Patriotis C, Pinsky PF, Thornquist MD, Scholler N, **Skates SJ**, Sluss PM, Srivastava S, Ward DC, Zhang Z, Zhu CS, Urban N. Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens. *Cancer Prev Res*. 2011; 4(3):365-74.
82. Zhu CS, Pinsky PF, Cramer DW, Ransohoff DF, Hartge P, Pfeiffer RM, Urban N, Mor G, Bast RC, Moore LE, Lokshin AE, McIntosh MW, **Skates SJ**, Vitonis A, Zhang Z, Ward DC, Symanowski JT, Lomakin A, Fung ET, Sluss PM, Scholler N, Lu KH, Marrangoni AM, Patriotis C, Srivastava S, Buys SS, Berg CD; for the PLCO Project Team. A Framework for Evaluating Biomarkers for Early Detection: Validation of Biomarker Panels for Ovarian Cancer. *Cancer Prev Res*. 2011; 4(3):375-383.
83. Moore RG, Miller MC, Disilvestro P, Landrum LM, Gajewski W, Ball JJ, **Skates SJ**. Evaluation of the diagnostic accuracy of the risk of ovarian malignancy algorithm in women with a pelvic mass. *Obstet Gynecol*. 2011; 118(2 Pt 1):280-8.
84. **Skates SJ**, Mai P, Horick NK, Piedmonte M, Drescher CW, Isaacs C, Armstrong DK, Buys SS, Rodriguez GC, Horowitz IR, Berchuck A, Daly MB, Domchek S, Cohn DE, Van Le L, Schorge JO, Newland W, Davidson SA, Barnes M, Brewster W, Azodi M, Nerenstone S, Kauff ND, Fabian CJ, Sluss PM, Nayfield SG, Kasten CH, Finkelstein DM, Greene MH, Lu K. Large Prospective Study of Ovarian Cancer Screening in High-Risk Women: CA125 Cut-Point Defined by Menopausal Status. *Cancer Prev Res*. 2011; 4(9):1401-8.
85. Creaney J, Yeoman D, Musk AW, de Klerk N, **Skates SJ**, Robinson BW. Plasma versus serum levels of osteopontin and mesothelin in patients with malignant mesothelioma-Which is best? *Lung Cancer*. 2011.
86. Moore RG, Miller MC, Steinhoff MM, **Skates SJ**, Lu KH, Lambert-Messerlian G, Bast RC. Serum HE4 levels are less frequently elevated than CA125 in women with benign gynecologic disorders. *Am J Obstet Gynecol*. 2012 Apr;206(4):351.e1-8. PMID: 22284961.



87. **Skates SJ**. Ovarian cancer screening: development of the risk of ovarian cancer algorithm (ROCA) and ROCA screening trials. *Int J Gynecol Cancer*. 2012 May;22 Suppl 1:S24-6. PMID: 22543916.
88. Bast RC, **Skates SJ**, Lokshin A, Moore RG. Differential diagnosis of a pelvic mass: improved algorithms and novel biomarkers. *Int J Gynecol Cancer*. 2012 May;22 Suppl 1:S5-8. PMID: 22543921; PMCID: PMC3389992.
89. Kuhn E, Whiteaker JR, Mani DR, Jackson AM, Zhao L, Pope ME, Smith D, Rivera KD, Anderson NL, **Skates SJ**, Pearson TW, Paulovich AG, Carr SA. Interlaboratory evaluation of automated, multiplexed peptide immunoaffinity enrichment coupled to multiple reaction monitoring mass spectrometry for quantifying proteins in plasma. *Mol Cell Proteomics*. 2012 Jun;11(6). PMID: 22199228; PMCID: PMC3433918.
90. Rosenthal AN, Fraser L, Manchanda R, Badman P, Philpott S, Mozersky J, Hadwin R, Cafferty FH, Benjamin E, Singh N, Evans DG, Eccles DM, **Skates SJ**, Mackay J, Menon U, Jacobs IJ. Results of annual screening in phase I of the United Kingdom familial ovarian cancer screening study highlight the need for strict adherence to screening schedule. *J Clin Oncol*. 2013 Jan 1;31(1):49-57.
91. Creaney J, Sneddon S, Dick IM, Dare H, Boudville N, Musk AW, **Skates SJ**, Robinson BW. Comparison of the diagnostic accuracy of the MSLN gene products, mesothelin and megakaryocyte potentiating factor, as biomarkers for mesothelioma in pleural effusions and serum. *Dis Markers*. 2013;35(2):119-27. doi:10.1155/2013/874212. PMID: 24167356; PMCID: PMC3774973.
92. Pinsky PF, Zhu C, **Skates SJ**, Black A, Partridge E, Buys SS, Berg CD. Potential effect of the risk of ovarian cancer algorithm (ROCA) on the mortality outcome of the Prostate, Lung, Colorectal and Ovarian (PLCO) trial. *Int J Cancer*. 2012 Oct 15. PMID: 23065684.
93. Abbatiello SE, Mani DR, Schilling B, Maclean B, Zimmerman LJ, Feng X, Cusack MP, Sedransk N, Hall SC, Addona T, Allen S, Dodder NG, Ghosh M, Held JM, Hedrick V, Inerowicz HD, Jackson A, Keshishian H, Kim JW, Lyssand JS, Riley CP, Rudnick P, Sadowski P, Shaddock K, Smith D, Tomazela D, Wahlander A, Waldemarson S, Whitwell CA, You J, Zhang S, Kinsinger CR, Mesri M, Rodriguez H, Borchers CH, Buck C, Fisher SJ, Gibson BW, Liebler D, Maccoss M, Neubert TA, Paulovich A, Regnier F, **Skates SJ**, Tempst P, Wang M, Carr SA. Design, Implementation, and Multi-Site Evaluation of a System Suitability Protocol for the Quantitative Assessment of Instrument Performance in LC-MRM-MS. *Mol Cell Proteomics*. 2013 May 20.
94. Lu KH, **Skates SJ**, Hernandez MA, Bedi D, Bevers T, Leeds L, Moore R, Granai C, Harris S, Newland W, Adeyinka O, Geffen J, Deavers MT, Sun CC, Horick N, Fritsche H, Bast RC. A 2-stage ovarian cancer screening strategy using the Risk of Ovarian Cancer Algorithm (ROCA) identifies early-stage incident cancers and demonstrates high positive predictive value. *Cancer*. 2013 Oct 1;119(19):3454-61. doi: 10.1002/ncr.28183. PMID: 23983047.
95. **Skates SJ**, Gillette MA, LaBaer J, Carr SA, Anderson L, Liebler DC, Ransohoff D, Rifai N, Kondratovich M, Težak Ž, Mansfield E, Oberg AL, Wright I, Barnes G, Gail M, Mesri M, Kinsinger CR, Rodriguez H, Boja ES. Statistical design for biospecimen cohort size in proteomics-based biomarker discovery and verification studies. *J Proteome Res*. 2013 Dec 6;12(12):5383-94. doi: 10.1021/pr400132j. PMID: 24063748.
96. Holman LL, Lu KH, Bast RC, Hernandez MA, Bodurka DC, **Skates SJ**, Sun CC. Risk perception, worry, and test acceptance in average-risk women who undergo ovarian cancer screening. *Am J Obstet Gynecol*. 2014 Mar; 210(3):257.e1-6. PMID: 24246524.
97. Creaney J, Dick IM, Meniawy TM, Leong SL, Leon JS, Demelker Y, Segal A, Bill Musk AW, Lee YC, **Skates SJ**, Nowak AK, Robinson BW. Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma. *Thorax*. 2014 Jul 18. pii: thoraxjnl-2014-205205. doi: 10.1136/thoraxjnl-2014-205205. PMID: 25037982
98. Sherman ME, Piedmonte M, Mai PL, Ioffe OB, Ronnett BM, Van Le L, Ivanov I, Bell MC, Blank SV, DiSilvestro P, Hamilton CA, Tewari KS, Wakeley K, Kauff ND, Yamada

- SD, Rodriguez G, **Skates SJ**, Alberts DS, Walker JL, Minasian L, Lu K, Greene MH. Pathologic Findings at Risk-Reducing Salpingo-Oophorectomy: Primary Results From Gynecologic Oncology Group Trial GOG-0199. *J Clin Oncol*. 2014 Oct 10;32(29):3275-83.
99. Moore RG, Hawkins DM, Miller MC, Landrum LM, Gajewski W, Ball JJ, Allard WJ, **Skates SJ**. Combining clinical assessment and the Risk of Ovarian Malignancy Algorithm for the prediction of ovarian cancer. *Gynecol Oncol*. 2014 Dec;135(3):547-51.
100. Menon U, Talaat A, Rosenthal AN, Macdonald ND, Jeyerajah AR, **Skates SJ**, Sibley K, Oram DH, Jacobs IJ. Performance of ultrasound as a second line test to serum CA125 in ovarian cancer screening. *BJOG*. 2014 Dec;121 Suppl 7:35-9. doi: 10.1111/1471-0528.13211.
101. Creaney J, Segal A, Olsen N, Dick IM, Musk AW, **Skates SJ**, Robinson BW. Pleural fluid mesothelin as an adjunct to the diagnosis of pleural malignant mesothelioma. *Dis Markers*. 2014; 2014:413946.
102. Schully SD, Carrick DM, Mechanic LE, Srivastava S, Anderson GL, Baron JA, Berg CD, Cullen J, Diamandis EP, Doria-Rose VP, Goddard KAB, Hankinson SE, Kushi LH, Larson EB, McShane LM, Schilsky RL, Shak S, **Skates SJ**, Urban N, Kramer BS, Khoury MJ, Ransohoff DF. Leveraging Biospecimen Resources for Discovery or Validation of Markers for Early Cancer Detection. *JNCI* 2015 Feb 16;107(4).
103. Abbatiello SE, Schilling B, Mani DR, Zimmerman LJ, Hall SC, MacLean B, Albertolle M, Allen S, Burgess M, Cusack MP, Ghosh M, Hedrick V, Held JM, Inerowicz HD, Jackson A, Keshishian H, Kinsinger CR, Lyssand J, Makowski L, Mesri M, Rodriguez H, Rudnick P, Sadowski P, Sedransk N, Shaddox K, **Skates SJ**, Kuhn E, Smith D, Whiteaker JR, Whitwell C, Zhang S, Borchers CH, Fisher SJ, Gibson BW, Liebler DC, MacCoss MJ, Neubert TA, Paulovich AG, Regnier FE, Tempst P, Carr SA. Large-scale inter-laboratory study to develop, analytically validate and apply highly multiplexed, quantitative peptide assays to measure cancer-relevant proteins in plasma. *Mol Cell Proteomics*. 2015 Sep;14(9):2357-74.
104. Vathipadiekal V, Wang V, Wei W, Waldron L, Drapkin R, Gillette M, **Skates SJ**, Birrer M. Creation of a Human Secretome: A Novel Composite Library of Human Secreted Proteins: Validation Using Ovarian Cancer Gene Expression Data and a Virtual Secretome Array. *Clin Cancer Res*. 2015 Nov 1;21(21):4960-9.
105. Menon U, Ryan A, Kalsi J, Gentry-Maharaj A, Dawney A, Habib M, Aspostolidou S, Singh N, Benjamin E, Burnell M, Davies S, Sharma A, Gnu R, Godfrey K, Lopes A, Oram D, Herod J, Williamson K, Seif MW, Jenkins H, Mould T, Woolas R, Murdoch J, Dobbs S, Amso NN, Leeson S, Cruickshank D, Scott I, Fallowfield L, Widschwendter M, Reynolds K, McGuire AJ, Campbell S, Parmar M, **Skates SJ**, Jacobs I. Risk algorithm using serial biomarker measurements doubles the number of screen-detected cancers compared to a single threshold rule in the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). *J Clin Oncol*. 2015 Jun 20;33(18):2062-71.
106. Jacobs IJ, Menon U, Ryan A, Gentry-Maharaj A, Burnell M, Kalsi JK, Amso NN, Apostolidou S, Benjamin E, Cruickshank D, Crump DN, Davies SK, Dawney A, Dobbs S, Fletcher G, Ford J, Godfrey K, Gunu R, Habib M, Hallett R, Herod J, Jenkins H, Karpinskyj C, Leeson S, Lewis SJ, Liston WR, Lopes A, Mould T, Murdoch J, Oram D, Rabideau DJ, Reynolds K, Scott I, Seif MW, Sharma A, Singh N, Taylor J, Warburton F, Widschwendter M, Williamson K, Woolas R, Fallowfield L, McGuire AJ, Campbell S, Parmar M, **Skates SJ**. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. *Lancet*. 2016 Mar 5;387(10022):945-56.
107. Russell MR, Walker MJ, Williamson AJ, Gentry-Maharaj A, Ryan A, Kalsi J, **Skates SJ**, D'Amato A, Dive C, Pernemalm M, Humphries PC, Fourkala EO, Whetton AD,

- Menon U, Jacobs I, Graham RL. Protein Z: A putative novel biomarker for early detection of ovarian cancer. *Int J Cancer*. 2016 Jun 15;138(12):2984-92.
108. Simmons AR, Clarke CH, Badgwell DB, Lu Z, Sokoll LJ, Lu KH, Zhang Z, Bast RC, **Skates SJ**. Validation of a Biomarker Panel and Longitudinal Biomarker Performance for Early Detection of Ovarian Cancer. *Int J Gynecol Cancer*. 2016 Jul;26(6):1070-7.
109. Mertins P, Mani DR, Ruggles KV, Gillette MA, Clauser KR, Wang P, Wang X, Qiao JW, Cao S, Petralia F, Kawaler E, Mundt F, Krug K, Tu Z, Lei JT, Gatza ML, Wilkerson M, Perou CM, Yellapantula V, Huang KL, Lin C, McLellan MD, Yan P, Davies SR, Townsend RR, **Skates SJ**, Wang J, Zhang B, Kinsinger CR, Mesri M, Rodriguez H, Ding L, Paulovich AG, Fenyö D, Ellis MJ, Carr SA. Proteogenomics connects somatic mutations to signalling in breast cancer.; NCI CPTAC. *Nature*. 2016 May 25;534(7605):55-62.
110. Anderson L, Razavi M, **Skates SJ**, Anderson NG, Pearson TW. Squeezing more value from the analytes we have: personal baselines for multiple analytes in serial DBS. *Bioanalysis*. 2016 Jun 9.
111. **Skates SJ**, Greene MH, Buys SS, Mai PL, Brown P, Piedmonte M, Rodriguez G, Schorge JO, Sherman M, Daly MG, Rutherford T, Brewster W, O'Malley DM, Partridge E, Boggess J, Drescher CW, Isaacs C, Berchuck A, Domchek S, Davidson SA, Edwards R, Elg SA, Wakeley K, Phillips K-A, Armstrong D, Horowitz I, Fabian CJ, Walker J, Sluss PM, Welch W, Minasian L, Horick NK, Kasten CH, Nayfield S, Alberts D, Finkelstein DM, Lu KH. Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk – Combined Results from Two Screening Trials. *Clinical Cancer Research* 31 Jan 2017.
112. Rosenthal AN, Fraser L, Philpott S, Manchanda R, Burnell M, Badman P, Hadwin R, Rizzuto I, Benjamin E, Singh N, Evans DG, Ryan A, Liston R, Dawnay A, Ford J, Gunu R, Mackay J, **Skates SJ**, Menon U, Jacobs IJ on behalf of UKFOCSS collaborators. Evidence of stage-shift in women diagnosed with ovarian cancer during Phase 2 of the UK Familial Ovarian Cancer Screening Study (UKFOCSS). *Journal of Clinical Oncology*. May 1;35(13):1411-1420. doi: 10.1200/JCO.2016.69.9330.
113. Gentry-Maharaj A, Glazer C, Burnell M, Ryan A, Berry H, Kalsi J, Woolas R, **Skates SJ**, Campbell S, Parmar M, Jacobs I, Menon U. Changing trends in reproductive/lifestyle factors in UK women: descriptive study within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). *BMJ Open*. 2017 Mar 6;7(3):e011822.
114. Yang WL, Gentry-Maharaj A, Simmons AR, Ryan A, Fourkala EO, Lu Z, Baggerly KA, Zhao Y, Lu K, Bowtell DDL, Jacobs I, **Skates SJ**, He WW, Menon U, Bast RC. Elevation of TP53 Autoantibody Prior to CA125 in Preclinical Invasive Epithelial Ovarian Cancer. *Clin Cancer Res*. 2017 Jun 21. pii: clincanres.0284.2017. doi: 10.1158/1078-0432.CCR-17-0284.
115. Menon U, McGuire AJ, Raikou M, Ryan A, Davies SK, Burnell M, Gentry-Maharaj A, Kalsi JK, Singh N, Amso NN, Cruickshank D, Dobbs S, Godfrey K, Herod J, Leeson S, Mould T, Murdoch J, Oram D, Scott I, Seif MW, Williamson K, Woolas R, Fallowfield L, Campbell S, **Skates SJ**, Parmar M, Jacobs IJ. The cost-effectiveness of screening for ovarian cancer: results from the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). *Br J Cancer*. 2017 Aug 22;117(5):619-627.
116. Stott W, Campbell S, Franchini A, Blyuss O, Zaikin A, Ryan A, Jones C, Gentry-Maharaj A, Fletcher G, Kalsi J, **Skates SJ**, Parmar M, Amso N, Jacobs I, Menon U. Self-reported transvaginal ultrasound visualization of normal ovaries in postmenopausal women is not reliable: results of expert review of archived images in UKCTOCS. *Ultrasound Obstet Gynecol*. 2018 Mar;51(3):401-408.

**Reviews, Chapters and Editorials**

1. Suit HD, Baumann M, **Skates S**, Convery K. Clinical interest in determinations of cellular radiation sensitivity. *Int J Radiat Biol.* 1989; 56(5):725-37. Review. PMID:2573670
2. Suit H, **Skates S**, Taghian A, Okunieff P, Efird JT. Clinical implications of heterogeneity of tumor response to radiation therapy. *Radiother Oncol.* 1992 Dec;25(4):251-60. Review. PMID:1480770
3. Carlson KJ, **Skates SJ**, Singer DE. Screening for ovarian cancer. *Ann Intern Med.* 1994; 121(2):124-32.
4. **Skates SJ**, Knapp RC. *Early Detection of Ovarian Cancer with Tumor Markers as First Line Test.* Mosby. 1996.
5. **Skates SJ**, Jacobs IJ, Knapp RC. Quantifying risk of ovarian cancer using longitudinal CA125 levels. *Ovarian Cancer 5, ISIS Medical Media* 1998, 187-198.
6. Bast RC, Urban N, Shridhar V, Smith D, Zhang Z, **Skates S**, Lu K, Liu J, Fishman D, Mills G. Early detection of ovarian cancer: promise and reality. *Cancer Treat Res.* 2002;107:61-97. Review. PMID:11775462
7. **Skates SJ**. Screening for ovarian cancer-risk, education, worry: path to appropriate use? *Gynecol Oncol.* 2002; 85(1):1-2.
8. Terry KL, Sluss PM, **Skates SJ**, Mok SC, Ye B, Vitonis AF, Cramer DW. Blood and urine markers for ovarian cancer: a comprehensive review. *Dis Markers.* 2004;20(2):53-70.
9. **Skates SJ**, Iliopoulos O. Molecular markers for early detection of renal carcinoma: investigative approach. *Clin Cancer Res.* 2004; 10(18 Pt 2):6296S-301S.
10. Baker SG, Kramer BS, McIntosh M, Patterson BH, Shyr Y, **Skates SJ**. Evaluating markers for the early detection of cancer: overview of study designs and methods. *Clin Trials.* 2006;3(1):43-56.
11. Bast RC, Badgwell D, Lu Z, Marquez R, Rosen D, Liu J, Baggerly KA, Atkinson EN, **Skates SJ**, Zhang Z, Lokshin A, Menon U, Jacobs I, Lu K. New tumor markers: CA125 and beyond. *Int J Gynecol Cancer.* 2005; 15 Suppl 3:274-81.
12. Bast RC, Brewer M, Zou C, Hernandez MA, Daley M, Ozols R, Lu K, Lu Z, Badgwell D, Mills GB, **Skates S**, Zhang Z, Chan D, Lokshin A, Yu Y. Prevention and early detection of ovarian cancer: mission impossible? *Recent Results Cancer Res.* 2007;174:91-100.
13. Rodriguez H, Tezak Z, Mesri M, Carr SA, Liebler DC, Fisher SJ, Tempst P, Hiltke T, Kessler LG, Kinsinger CR, Philip R, Ransohoff DF, **Skates SJ**, Regnier FE, Anderson NL, Mansfield E; Workshop Participants. Analytical validation of protein-based multiplex assays: a workshop report by the NCI-FDA interagency oncology task force on molecular diagnostics. *Clin Chem.* 2010; 56(2):237-43 PMID: 20007859.
14. **Skates SJ**. A statistical challenge: developing tests for biomarker utility specific to the intended use. *J Natl Cancer Inst.* 2014 Apr 1;106(4):dju076. PMID: 24681600
15. Jacobs IJ, Parmar M, **Skates SJ**, Menon U. Ovarian cancer screening: UKCTOCS trial - Authors' reply. *Lancet.* 2016 Jun 25;387(10038):2603-4.
16. **Skates SJ**. EPIC Early Detection of Ovarian Cancer. *Clin Cancer Res.* 2016 Sep 15;22(18):4542-4.